세계의 안와 위축증 시장(2023-2030년)

Overview

The Foveal atrophy market is driven by factors such as the aging population, advances in technology, increasing research and development, patient awareness and education, and regulatory approvals.

A small, focal, poorly defined, hypopigmented foveal or juxtafoveal lesion is referred to as focal foveal atrophy when it is present but the rest of the retina is unharmed. The fovea centralis, often known as the fovea, is a tiny depression located in the neurosensory retina that has the best visual acuity. The macula's fovea, which is in the center and is responsible for central vision, is by itself.

Numerous macular, vascular, genetic, inflammatory, toxic, and traumatic retinal illnesses can all be accompanied by foveal atrophy. It is typically categorized under the general heading of geographic atrophy in people with age-related macular degeneration, myopic degeneration, angioid streaks, long-term cystoid macular edema from any source, and macular dystrophies.

It is also sometimes referred to as macular atrophy due to other retinal illnesses. In some retinal illnesses, such as macular phototoxicity and resolved central serous chorioretinopathy, atrophy typically manifests as a tiny lesion. Atrophy can occasionally develop in the foveal or juxtafoveal area.

Market Dynamics

The Increasing Research Activities are Driving the Global Foveal Atrophy Market Growth

One application of half-dose photodynamic treatment (PDT) targeting the fovea was found to be structurally and functionally advantageous for treating individuals with chronic central serous chorioretinopathy (CSC), and they did not experience foveal atrophy. A single half-dose PDT with a treatment location that included the fovea was administered to a total of 57 patients with chronic CSC.

At baseline and numerous visits after therapy, optical coherence tomography scans and fundus autofluorescence images were examined for structural improvement and potential atrophic development. According to researchers, the external limiting membrane and ellipsoid zone integrity on optical coherence tomography, as well as hypoautofluorescence on fundus autofluorescence, were the primary outcome measures.

The Aging Population Boost the Global Foveal Atrophy Market Growth

The development and progression of foveal atrophy are significantly influenced by the aging population, particularly in the context of age-related macular degeneration (AMD). With age, the likelihood of developing AMD and foveal atrophy greatly rises. Over the age of 50, there is a significant increase in the risk of having AMD, and the risk keeps rising with age. This is due to the fact that the eyes' natural aging process renders them more vulnerable to harm and deterioration.

Cellular changes and accumulative harm to several tissues, including the retina, are part of the aging process. This may eventually have an effect on the health and functionality of the cells in the macula, causing foveal atrophy.

Challenges with Foveal Atrophy are Hampering the Global Foveal Atrophy Market Growth

Although there have been improvements in the ways that foveal atrophy can be treated, illnesses like AMD or Stargardt disease, which cause foveal atrophy, still have no known cure. This may restrict patients' alternatives and slow market expansion. Anti-VEGF injections are one example of a therapy option that might be costly and may need to be administered frequently. For certain patients, especially in areas with insufficient healthcare coverage, this may limit their access to treatment. Foveal atrophy frequently results from multifactorial, complicated diseases like AMD. It can be difficult to create focused medicines that go at the root problems.

Segment Analysis

The global foveal atrophy market is segmented based on type, drug class, treatment, end-user and region.

The Pharmacological Interventions Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The pharmacological interventions segment accounted for the highest market stake accounting for approximately 41.2% of the foveal atrophy market in 2022. Pharmacological interventions, which include those that deal with disorders like age-related macular degeneration (AMD) and stargardt disease that cause foveal atrophy, refer to the use of pharmaceuticals and treatments to treat a variety of illnesses. Wet AMD, a type of AMD characterized by aberrant blood vessel formation beneath the retina, is commonly treated with anti-VEGF (vascular endothelial growth factor) medication.

These aberrant blood arteries can cause bleeding and leakage, which exacerbates foveal atrophy. Anti-VEGF medications are injected into the eye to stop the development of these vessels, lessen leaking, and stop the disease's progression. Ranibizumab, aflibercept, and bevacizumab are typical anti-VEGF medications.

Geographical Penetration

North America Holds a Dominant Position in the Global Foveal Atrophy Market

North America is estimated to hold around 1/3rd of the total market share throughout the forecast period. Due to longer life expectancies and the aging baby boomer generation, the United States is quickly aging. Age-related eye disorders including age-related macular degeneration (AMD), which can cause foveal atrophy, are more common as people get older.

The United States has a strong healthcare system with cutting-edge medical equipment, research centers, and therapeutic alternatives. This encourages the early recognition, evaluation, and management of disorders such as foveal atrophy.

Competitive Landscape

The major global players in the market include: Novartis AG, Regeneron Pharmaceuticals, Genetech, AbbVie among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the foveal atrophy market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. The infrastructure and healthcare systems in affected areas can be strained by conflict and war. Emergency medical demands may have taken priority over healthcare, especially the treatment of disorders like foveal atrophy that affect the eyes.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the foveal atrophy market to improve various aspects of drug development. AI-driven simulations and data analysis can hasten the development of new foveal atrophy drugs. In order to develop new therapeutics, AI systems can forecast how prospective treatments would impact retinal cells.

By Type

• Uveitic Foveal Atrophy
• Focal Foveal Atrophy

By Drug class

• Anti-VEGF Therapy
• Gene Therapy
• Others

By Treatment

• Pharmacological Interventions
• Surgical Interventions

By End-user

• Ophthalmology Clinics
• Hospitals
• Research Institutions

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Why Purchase the Report?

• To visualize the global foveal atrophy market segmentation based on the type, drug class, treatment, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of foveal atrophy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of critical products of all the major players.

The global foveal atrophy market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Treatment
• 3.4. Snippet by End-user
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Aging population
  • 4.1.2. Restraints
    • 4.1.2.1. Challenges associated with Foveal Atrophy
  • 4.1.3. Opportunity
    • 4.1.3.1. Technological advancements
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.1.2. Market Attractiveness Index, By Type
• 9.2. Uveitic Foveal Atrophy*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Focal Foveal Atrophy

10. By Drug Class

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.1.2. Market Attractiveness Index, By Drug Class
• 10.2. Anti-VEGF Therapy*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Gene Therapy
• 10.4. Others

11. By End-user

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 11.1.2. Market Attractiveness Index, By End-user
• 11.2. Ophthalmology Clinics*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Hospitals
• 11.4. Research Institutions

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.7.1. U.S.
    • 12.2.7.2. Canada
    • 12.2.7.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.7.1. Germany
    • 12.3.7.2. U.K.
    • 12.3.7.3. France
    • 12.3.7.4. Italy
    • 12.3.7.5. Spain
    • 12.3.7.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.7.1. Brazil
    • 12.4.7.2. Argentina
    • 12.4.7.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.7.1. China
    • 12.5.7.2. India
    • 12.5.7.3. Japan
    • 12.5.7.4. Australia
    • 12.5.7.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Novartis AG*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Regeneron Pharmaceuticals
• 14.3. Genetech
• 14.4. AbbVie
• 14.5. Others

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us